Picture of Giant Biogene Holding Co logo

2367 Giant Biogene Holding Co Cashflow Statement

0.000.00%
hk flag iconLast trade - 00:00
Consumer DefensivesAdventurousLarge CapFalling Star

Annual cashflow statement for Giant Biogene Holding Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line9731,1781,7452,4582,350
Depreciation
Amortisation
Non-Cash Items-28.331.7-53.9-54.8-166
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-275-305-77.9-411-486
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities6929321,6472,0411,781
Capital Expenditures-111-153-228-247-429
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items1,674-705-299-859110
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities1,563-859-527-1,106-319
Financing Cash Flow Items-2,619-379-3.54-7.97-11.3
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities4,476-5,79051.8583918
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash6,735-5,7721,1731,5262,276